A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer (NCT03981796)
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
🩺 Plain-English Summary (8th-Grade Level)
This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (169 Sites)
Showing the first 25 of 169 sites.
- GSK Investigational Site — Phoenix, Arizona
- GSK Investigational Site — Scottsdale, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Tucson, Arizona
- GSK Investigational Site — Newport Beach, California
- GSK Investigational Site — Palo Alto, California
- GSK Investigational Site — Deerfield Beach, Florida
- GSK Investigational Site — Jacksonville, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Orlando, Florida
- GSK Investigational Site — Atlanta, Georgia
- GSK Investigational Site — Augusta, Georgia
- GSK Investigational Site — Savannah, Georgia
- GSK Investigational Site — Hinsdale, Illinois
- GSK Investigational Site — Zion, Illinois
- GSK Investigational Site — Fort Wayne, Indiana
- GSK Investigational Site — Indianapolis, Indiana
- GSK Investigational Site — Indianapolis, Indiana
- GSK Investigational Site — Iowa City, Iowa
- GSK Investigational Site — Lexington, Kentucky
- GSK Investigational Site — Covington, Louisiana
- GSK Investigational Site — New Orleans, Louisiana
- GSK Investigational Site — Shreveport, Louisiana
- GSK Investigational Site — Boston, Massachusetts
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Neoplasms
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers — St Louis, Missouri
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) — Goodyear, Arizona
- Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors — Birmingham, Alabama
- Hispanic Adapted and Culturally Relevant Exercising Together — Tucson, Arizona
- M7824 Related Adverse Effects in Adults With Cancer — Bethesda, Maryland
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors — Duarte, California
Explore by condition: All Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.